2022
Epidemiology and outcomes of surgical site infections among pediatric liver transplant recipients
Banach DB, Lopez‐Verdugo F, Sanchez‐Garcia J, Tran A, Gomez‐Llerena A, Munoz‐Abraham A, Bertacco A, Valentino PL, Yoo P, Dembry L, Mulligan DC, Ekong UD, Emre SH, Rodriguez‐Davalos M. Epidemiology and outcomes of surgical site infections among pediatric liver transplant recipients. Transplant Infectious Disease 2022, 24: e13941. PMID: 35989545, DOI: 10.1111/tid.13941.Peer-Reviewed Original ResearchConceptsSurgical site infectionLiver transplant recipientsLiver transplantationBiliary complicationsGraft recipientsTransplant recipientsSite infectionRisk factorsOutcomes of SSIPediatric liver transplant recipientsLong-term graftPediatric liver transplantationRetrospective descriptive analysisPrimary endpointHospital daysPatient agePediatric populationPatient survivalSignificant causeComplicationsPatientsRecipientsOutcomesInfectionIncidence
2018
Successful treatment of primary donor‐derived human herpesvirus‐8 infection and hepatic Kaposi Sarcoma in an adult liver transplant recipient
Fu W, Merola J, Malinis M, Lacy J, Barbieri A, Liapakis AH, Mulligan DC, Yoo PS. Successful treatment of primary donor‐derived human herpesvirus‐8 infection and hepatic Kaposi Sarcoma in an adult liver transplant recipient. Transplant Infectious Disease 2018, 20: e12966. PMID: 30014622, DOI: 10.1111/tid.12966.Peer-Reviewed Case Reports and Technical NotesConceptsHuman herpesvirus 8 infectionHepatic Kaposi sarcomaKaposi's sarcomaTransplant recipientsAdult liver transplant recipientsRegression of KSSplit liver transplantAcute cellular rejectionLiver transplant recipientsSuccessful therapeutic strategiesAllograft functionCellular rejectionLiver transplantSeropositive donorsSuccessful treatmentLiposomal doxorubicinTherapeutic strategiesRecipientsSarcomaInfectionTreatmentImmunosuppressionPatientsMalignancyTransplant
2015
Tu1044 Sofosbuvir-Based Interferon-Free Regimens for Hepatitis C Infection in Patients With Compensated and Decompensated Cirrhosis: Interim Analysis of a Prospective Observational Cohort
Do A, Lim J, Liapakis A, Babas G, Caldwell C, Fortune B, Emre S, Kulkarni S, Lempit S, Mistry P, Mulligan D, Rodriguez-Davalos M, Schilsky M, Tichy E, Yoo P, Jakab S. Tu1044 Sofosbuvir-Based Interferon-Free Regimens for Hepatitis C Infection in Patients With Compensated and Decompensated Cirrhosis: Interim Analysis of a Prospective Observational Cohort. Gastroenterology 2015, 148: s-1094-s-1095. DOI: 10.1016/s0016-5085(15)33733-1.Peer-Reviewed Original Research
2007
Hemosuccus Pancreaticus in the Era of Capsule Endoscopy and Double Balloon Enteroscopy Complicated by Multifocal Mycobacterium chelonae/abscessus Infection
Pasha SF, Blair JE, Garvey PB, Gray RJ, Mulligan DC, Collins JM, Heigh RI. Hemosuccus Pancreaticus in the Era of Capsule Endoscopy and Double Balloon Enteroscopy Complicated by Multifocal Mycobacterium chelonae/abscessus Infection. Case Reports In Gastroenterology 2007, 1: 38-47. PMID: 21487470, PMCID: PMC3073786, DOI: 10.1159/000104977.Peer-Reviewed Original ResearchHemosuccus pancreaticusAbscessus infectionCapsule endoscopyObscure gastrointestinal bleedingDouble-balloon enteroscopyVideo capsule endoscopyGastrointestinal bleedingGastrointestinal findingsMultiple endoscopiesRadiologic evaluationBalloon enteroscopyRare etiologySurgical interventionPancreatic ductEndoscopyDiagnosisBleedingPatientsInfectionEnteroscopyComplicatedEtiologyMonthsCoccidioidomycosis masked by symptoms of end‐stage liver disease in transplant candidates
Sachdev MS, Blair JE, Mulligan DC, Kusne S. Coccidioidomycosis masked by symptoms of end‐stage liver disease in transplant candidates. Transplant Infectious Disease 2007, 9: 153-155. PMID: 17462003, DOI: 10.1111/j.1399-3062.2007.00215.x.Peer-Reviewed Original ResearchCoccidioidomycosis in healthy persons evaluated for liver or kidney donation
Blair JE, Mulligan DC. Coccidioidomycosis in healthy persons evaluated for liver or kidney donation. Transplant Infectious Disease 2007, 9: 78-82. PMID: 17313480, DOI: 10.1111/j.1399-3062.2006.00179.x.Peer-Reviewed Original ResearchConceptsDonor-derived coccidioidomycosisKidney donationTransplant recipientsHealthy personsDonor candidatesOrgan donor candidatesRisk of transmissionProphylaxis protocolLiver donationFourth patientCoccidioidal antibodiesPossible liverCoccidioidomycosisFungal infectionsCoccidioides speciesRecipientsFurther studiesPatientsLiverRiskDonationProphylaxisUnique challengesInfectionPrevalence
2005
Hepatic B‐cell non‐Hodgkin's lymphoma of MALT type in the liver explant of a patient with chronic hepatitis C infection
Orrego M, Guo L, Reeder C, De Petris G, Balan V, Douglas DD, Byrne T, Harrison E, Mulligan D, Rodriguez‐Luna H, Moss A, Reddy K, Rakela J, Vargas HE. Hepatic B‐cell non‐Hodgkin's lymphoma of MALT type in the liver explant of a patient with chronic hepatitis C infection. Liver Transplantation 2005, 11: 796-799. PMID: 15973702, DOI: 10.1002/lt.20384.Peer-Reviewed Original ResearchConceptsLiver transplantationHodgkin's lymphomaB cellsChronic hepatitis C infectionHepatitis C virus infectionHepatic B cellsC virus infectionHepatitis C infectionMarginal zone lymphomaC infectionCirrhotic patientsVirus infectionB-NHLLiver explantsMALT typeLymphomaClinical settingCommon typePatientsInfectionComplicationsTransplantationLiver transplant in a patient with a ventriculoperitoneal shunt
Faybush E, Mulligan DC, Birch BD, Sirven JI, Balan V. Liver transplant in a patient with a ventriculoperitoneal shunt. Liver Transplantation 2005, 11: 467-468. PMID: 15776410, DOI: 10.1002/lt.20371.Peer-Reviewed Original ResearchConceptsVentriculoperitoneal shuntLiver transplantationNeurological complicationsTheoretical contraindicationGraft survivalLiver transplantMinor complicationsAccounts of patientsShunt conversionPatientsTransplantationComplicationsShuntNeurological perspectiveDeleterious effectsCirrhosisPosttransplantationVentriculoperitonealContraindicationsTransplantGraftInfection
2004
Hepatitis C Virus Quasi-Species Dynamics Predict Progression of Fibrosis after Liver Transplantation
Arenas JI, Gallegos-Orozco JF, Laskus T, Wilkinson J, Khatib A, Fasola C, Adair D, Radkowski M, Kibler KV, Nowicki M, Douglas D, Williams J, Netto G, Mulligan D, Klintmalm G, Rakela J, Vargas HE. Hepatitis C Virus Quasi-Species Dynamics Predict Progression of Fibrosis after Liver Transplantation. The Journal Of Infectious Diseases 2004, 189: 2037-2046. PMID: 15143471, DOI: 10.1086/386338.Peer-Reviewed Original ResearchMeSH Keywords5' Untranslated RegionsDisease ProgressionElectrophoresis, Polyacrylamide GelFemaleGenetic VariationHepacivirusHepatitis C, ChronicHumansLiver CirrhosisLiver TransplantationMaleMiddle AgedPhylogenyPolymorphism, Single-Stranded ConformationalReverse Transcriptase Polymerase Chain ReactionRNA, ViralViral Envelope ProteinsConceptsOrthotopic liver transplantationHepatitis C virusLiver transplantationGroup 1Quasi speciesSeverity of recurrenceGroup 1 patientsGroup 2 patientsE2 regionProgression of fibrosisPost-OLT periodCourse of infectionHeteroduplex mobility assayHCV complexityHCV infectionC virusGroup 2PatientsTransplantationSingle-strand conformational polymorphismLiver samplesInfectionWeeksQuasi-species dynamicsYears
2002
A randomized, prospective, double-blinded evaluation of selective bowel decontamination in liver transplantation
Hellinger WC, Yao JD, Alvarez S, Blair JE, Cawley JJ, Paya CV, O’Brien P, Spivey JR, Dickson RC, Harnois DM, Douglas DD, Hughes CB, Nguyen JH, Mulligan DC, Steers JL. A randomized, prospective, double-blinded evaluation of selective bowel decontamination in liver transplantation. Transplantation 2002, 73: 1904-1909. PMID: 12131685, DOI: 10.1097/00007890-200206270-00009.Peer-Reviewed Original ResearchConceptsSelective bowel decontaminationLiver transplantationRate of infectionDay 0Bowel decontaminationMedical careBacterial infectionsDouble-blinded fashionDouble-blinded evaluationGentamicin 80Mortal complicationsUncontrolled trialsSwab culturesTreatment groupsTransplantationPatientsDay 21Day 60Routine useInfectionPositive floraNegative floraFecal cultureCareDeath
2001
Increased prevelance of osteoporosis in patients with end-stage liver diseasse secondary to hepatitis C infection and alcohol
Yosfi M, Douglas D, Rakela J, Savage W, Mulligan D, Harrison M, Vargas H, Eberhard K, Moss A, Balan V. Increased prevelance of osteoporosis in patients with end-stage liver diseasse secondary to hepatitis C infection and alcohol. Gastroenterology 2001, 120: a378. DOI: 10.1016/s0016-5085(08)81877-x.Peer-Reviewed Original ResearchIncreased prevelance of osteoporosis in patients with end-stage liver diseasse secondary to hepatitis C infection and alcohol
YOSFI M, DOUGLAS D, RAKELA J, SAVAGEIII W, MULLIGAN D, HARRISON M, VARGAS H, EBERHARD K, MOSS A, BALAN V. Increased prevelance of osteoporosis in patients with end-stage liver diseasse secondary to hepatitis C infection and alcohol. Gastroenterology 2001, 120: a378-a378. DOI: 10.1016/s0016-5085(01)81877-1.Peer-Reviewed Original Research